Evaluate changes in health-related quality of life (HRQOL) and disability in children with systemic juvenile idiopathic arthritis (sJIA) or polyarticular juvenile idiopathic arthritis (pJIA) treated with tocilizumab.
Secondary analyses of two double-blind, placebo-controlled trials of intravenous tocilizumab in children with active sJIA or pJIA were conducted. Patient-reported outcomes of disability (Childhood Health Assessment Questionnaire [CHAQ]), HRQOL (Child Health Questionnaire-Parent Form-50 [CHQ-P50]; health concepts, physical summary score [CHQ-P50-PhS]; psychosocial summary score [CHQ-P50-PsS]), pain, and well-being (100-mm visual analog scale [VAS]) were measured at weeks 0 and 12 (sJIA), 16 and 40 (pJIA), and 104.
112 sJIA and 188 pJIA patients entered the trials. At week 16, pJIA patients’ mean ± SD CHAQ decreased from 1.39 ± 0.74 at baseline to 0.67 ± 0.65 (P < 0.001). At week 12, sJIA patients' mean CHQ-P50-PhS improved more with tocilizumab than placebo (7.3 ± 10.2 vs 2.4 ± 10.6; P < 0.05). Almost all mean CHQ-P50 health concept scores, CHQ-P50-PsS, and CHQ-P50-PhS improved (P ≤ 0.002) by week 104 for patients with sJIA. pJIA and sJIA patients showed significant (P < 0.001) reductions in disability (mean CHAQ scores: -1.09 ± 0.71; -1.17 ± 0.80), improvements in well-being (-43.76 ± 26.61; -51.53 ± 23.57), and decreases in pain (-41.56 ± 31.06; -51.26 ± 26.79); 92.9%/96.8% of tocilizumab-treated pJIA/sJIA patients reported no more than minimal pain (VAS ≤35 mm) at week 104.
Tocilizumab treatment was associated with significantly reduced disability and pain and improved HRQOL in sJIA and pJIA patients.

This article is protected by copyright. All rights reserved.

References

PubMed